(NASDAQ:ICPT) will announce $26.70 million in sales for the current quarter, Zacks reports. Analysts will likely revise their estimates leading in to the actual results date. Intercept Pharmaceuticals posted sales of $5.52 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 383.7%. For the current year, analysts are predicting earnings of $2.00 per share according to First Call. The sell-side analysts are projecting earnings per share of $0.58 for the next fiscal quarter. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The firm had revenue of $21 million during the quarter, compared to analyst estimates of $15.88 million. During the same quarter in the prior year, the company earned ($5.17) EPS. Intercept Pharmaceuticals had 28 analyst reports since August 10, 2015 according to SRatingsIntel. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. Below is a list of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) latest ratings and price target changes. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a "sell" rating to a "hold" rating and set a $115.00 price target for the company in a report on Friday, May 5th. Sell-side research firms now have a consensus one year price target of $25.53 on the stock according to First Call. Credit Suisse Group set a $201.00 price objective on shares of Intercept Pharmaceuticals and gave the stock a "buy" rating in a research report on Saturday, June 3rd. Cowen and Company restated a "buy" rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Intercept Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $190.98.
In related news, CMO David Shapiro sold 1,117 shares of the stock in a transaction on Monday, May 1st. They now have a Dollars 60 price target on the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The shares were sold at an average price of $110.73, for a total value of $77,289.54. The disclosure for this sale can be found here. Insiders sold a total of 4,016 shares of company stock valued at $452,624 over the last quarter. Wedbush restated an "outperform" rating and set a $224.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, March 17th. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 132 shares during the period. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since June 22, 2016 and is downtrending. Bank of Montreal Can now owns 24,977 shares of the biopharmaceutical company's stock worth $2,824,000 after buying an additional 13,606 shares during the last quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company's stock worth $1,674,000 after buying an additional 1,339 shares during the last quarter. Finally, Numeric Investors LLC purchased a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at about $253,000. State Street Corp now owns 751,027 shares of the biopharmaceutical company's stock worth $81,600,000 after buying an additional 126,011 shares during the last quarter. Following the transaction, the chief marketing officer now directly owns 45,465 shares of the company's stock, valued at approximately $4,933,407.15.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, May 4th.
Mourners remember U.S. student held prisoner by North Korea
He returned in a vegetative state, unable to communicate with his family and with devastating brain loss. Otto Warmbier coached Cain's son in swimming and "made a great impression on him", she said.
The Wall Street analysts who cover Devon Energy Corporation (NYSE:DVN) shares are providing price target projections on the company. This company shares are 39.14% off its target price of $178.66 and the current market capitalization stands at $3.2B. The stock price recently experienced a 5-day gain of 89.73% with 0.66 average true range (ATR).
Intercept Pharmaceuticals, Inc. has a 12 month low of $96.63 and a 12 month high of $177.93.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and worldwide copyright laws. Van ECK Associates Corp boosted its position in shares of Intercept Pharmaceuticals by 9.2% in the first quarter. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.
- Petra Kvitova reaches semifinals at Aegon Classic
- Danny Ainge hints that the Celtics weren't going to take Markelle Fultz
- Raikkonen prepared to sacrifice himself to help Vettel
- Showers, scattered storms expected Friday; Tropical moisture Saturday
- Le deuxième gouvernement de la présidence Macron annoncé
- Formula 1 in Baku organized very well: German tourist
- Remaniement: Découvrez les nouveaux ministres du gouvernement "Philippe II"
- Dennis Rodman Says We're All Misunderstanding Kim Jong
- Final Advisory Issued On Cindy! More Rain in the Forecast
- Gorkhas of Arunachal rally for Gorkhaland